Method of prolonging the survival of a subject with als
IL330531A0Pending Publication Date: 2026-08-01PRILENIA NEUROTHERAPEUTICS LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- IL330531
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-18
- Filing Date
- 2025-01-16
- Publication Date
- 2026-08-01
AI Technical Summary
Technical Problem
Current treatments for Amyotrophic Lateral Sclerosis (ALS) provide only modest effects on disease progression and survival, with most patients dying within 3-10 years of diagnosis, and there is a need for more effective methods to prolong the survival of ALS patients.
Method used
Administering pridopidine or its pharmaceutically acceptable salts to ALS patients, which acts as a high-affinity SIR ligand, activating the SIR protein to provide neuroprotective effects and prolong survival by 2-24 months compared to untreated patients.
Benefits of technology
Prolongs the survival of ALS patients by 2-24 months, offering a clinically meaningful increase in survival probability and improving functional outcomes.
✦ Generated by Eureka AI based on patent content.
Abstract
This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art